Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...

Assistant Teaching Professor of Global Arts, Media and Writing Studies, University of California, Merced Ordinary and universal, the act of writing changes the brain. From dashing off a heated text ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best mid cap stocks to buy according to hedge funds. On November 1, TD Cowen analyst Brendan Smith touted the progress the company has made ...

NASHVILLE, Tenn. (WSMV) - Tennessee’s new private school voucher program, which provides $7,300 to 20,000 students in its first year, could more than double in size in 2026, a move projected to cost ...

DNA Vibe appointed Maria Del Rio as its chief marketing officer. Magnet Biomedicine appointed Bharat Reddy as chief business officer. Target RWE named Sriram Krishnan, PhD as chief product officer.

A growing number of special education teachers say they use artificial intelligence platforms to draft all or part of students’ individualized education programs, even as many districts lack policies ...

When financial writers discuss money, the focus is usually on acquisition—i.e., how to maximize your portfolio. I’ve contributed my fair share to the pile of advice, which can be distilled into this ...

For many retirees, the challenge isn't just making their money last. It's figuring out how to access the wealth they've already built. With inflation still pushing up the cost of groceries, gas and ...

On August 12, 2025, the Board approved a reverse stock split of the Company’s outstanding shares of Common Stock at a ratio of one-for-five (the “Reverse Stock Split”). The Reverse Stock Split is ...